Alembic has received the Food and Drug Administration’s permission for entacapone tablets in a dosage strength of 200 mg.
The product is the generic of Orion’s Comtan.
[Read more: Alembic obtains FDA nod for 2 generics]
The drug is indicated as an adjunct to levodopa and carbidopa to treat end-of-dose "wearing-off" in patients with Parkinson's disease.
Entacapone tablets, 200 mg have a market value of roughly $10.5 million for the 12 months ending September 2021, according to IQVIA.
Read more: Alembic debuts generic Zebeta]